Slide Shows


From Bumpkins to Beaches: The 10 Crappiest U.S. States To Do Business Cue the banjos -- the following states figure in the list of 10 Worst States for Business in America.

Biotech Stocks Facing FDA Decision In May Another busy month at the FDA is coming to an end, and it’s that time again to take a look at the upcoming action dates of approval, and panel review dates in May.

The 10 Best-Selling Drugs Of The Year Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV or HCV infections. According to insurance industry group America’s Health Insurance Programs or AHIP, drug spending in the U.S. is projected to rise to $590 billion by 2020 from $337 billion in 2015. Drug approvals by the U.S. Food and Drug Administration touched a 21-year high in 2017. Novel drug approvals by the FDA totaled 46 in 2017, up from 22 in the prior year. Novel drugs are new molecular entities or NMEs having chemical structures that have never been approved before.

10 CEOs Forced Out By Sex Scandal Recent times have seen many high-profile men forced to leave their jobs, amid a cultural shift where more women are coming forward alleging sexual harassment by their bosses. The percentage of CEOs getting pushed out for questionable behavior is up in recent years, and sexual misconduct played a prominent part in many of them. There is a national conversation going on about sexual harassment in the United States, which witnessed campaigns such as #Me Too, a number of protest rallies, and the media exposing predators.

Potential Treatments For Sickle Cell Disease Sickle cell disease, or SCD in short, refers to a group of inherited red blood cell disorders. In these patients, the hemoglobin protein present inside the red blood cells is abnormal, causing the RBCs to become rigid, sticky and "C" or sickle, shaped. The faulty hemoglobin is known as sickle hemoglobin (HbS), and is caused by a mutation. It is estimated that about 70,000 to 100,000 Americans have sickle cell disease.

Potential Blockbuster Drugs The journey of drugs from bench to bedside is a roller coaster ride. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.

Biggest Losers: The Ten Worst Stocks Of The First Quarter Despite March historically being a good month for U.S. stock markets, March 2018 has belied expectations. Worries about rising interest rates and more recently, concerns about global trade wars have roiled stock markets this month. Markets saw the Federal Reserve’s first rate hike earlier in March 2018 when the central bank announced it’s widely anticipated decision to raise interest rates by 25 basis points and also continued to project three rate hikes in 2018.  The Dow and S&P 500 indices are now on track for the worst March performance since 2001. For the trading week ended Friday March 23, the major averages posted their biggest weekly loss since January 2016 amid lingering trade war concerns.

Biotech Stocks Facing FDA Decision in April Although nothing much happened in terms of approvals, March was a fairly busy month for the FDA on a number of fronts.

Murder Towns USA: The 10 Most Dangerous Cities in Our Nation Although rates of occurrences of criminal offences have dropped, America continues to witness an unusually large number of deaths by assault.

New Drugs Approved in February Yet another month has gone by, during which, headlines were dominated by flu blues. In the wake of influenza season, which may continue to affect Americans into April, the FDA is stepping up efforts to help improve the effectiveness of influenza vaccines. This year’s influenza vaccines are said to have produced reduced effectiveness against one strain of influenza A, called H3N2. On the regulatory front, here’s bit of what happened in February. Three *novel drugs were approved last month.  *Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before. Gilead Sciences' Biktarvy for the treatment of HIV-1 infection, Vertex Pharmaceuticals' Symdeko for treating the underlying cause of cystic fibrosis, Janssen Pharmaceuticals' Erleada for prostate cancer, are the new molecular entities that were approved last month. Now, let’s have a look at the full list of drugs, including novel drugs, to have gained the regulatory nod in the U.S. in February.